Business
AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect
AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes
About this update from Angiodynamics, Inc.
[{"type":"text","content":"\nAngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that Palmetto GBA has issued a final Local Coverage Determination (LCD L40205) establishing Medicare coverage guidance for irreversible electroporation (IRE), the non-thermal ablation technology delivered by the Company's NanoKnife System, in two clinical indications: favorable intermediate-risk prostate cancer and metastatic colorectal cancer to the liver. The final LCD becomes effective July 5, 2026.\n\n\nThe final LCD advances a reimbursement infrastructure already underway. Effective January 1, 2026, the American Medical Association CPT® Editorial Panel activated Category I CPT codes for IRE procedures in the prostate and liver, representing the AMA's formal recognition that a procedure is clinically effective, reflects widespread physician adoption, and carries established clinical value. Category I codes include physician Relative Value Units (RVUs) and support standardized billing across hospital outpatient departments and ambulatory surgical center settings. The Palmetto GBA LCD provides the corresponding coverage framework, enabling eligible patients and treating physicians to access reimbursement for IRE procedures under Medicare and marking an important step toward broader national payer adoption.\n\n\n“The Palmetto GBA final LCD advances patient access to IRE as a recognized treatment option for appropriately selected patients,” said Juan Carlos Serna, AngioDynamics Senior Vice President of Scientific and Clinical Affairs. “For men with favorable intermediate-risk prostate cancer, focal therapy that targets the cancer while preserving the structures that affect urinary and sexual function addresses a real quality-of-life need. With Category I CPT codes now in place for prostate and liver procedures, and explicit coverage guidance from Palmetto GBA, we are in a strong position to support treating physicians and to continue building patient access across additional payer jurisdictions.”\n\n\nUnder LCD L40205, effective July 5, 2026, Palmetto GBA covers IRE in the following settings:\n\nFavorable intermediate-risk prostate cancer grade group 2 (Gleason Score 3+4): For appropriately selected patie...